“…A recent meta-analysis43 performed on CLE and gastric diseases, focused on three domains: (1) detection and diagnosis of polyps and neoplastic lesions (three studies, sensitivity 85% (95% CI 78% to 91%, I 2 =52.3%), specificity 99% (95% CI 98% to 99%, I 2 =92.92%), AUC=0.929), (2) gastritis and gastric metaplasia (six studies, sensitivity 94% (95% CI 92% to 96%, I 2 =54.8%), specificity 95% (CI 92% to 97%, I 2 =55.6%), AUC=0.983) and (3) H. pylori -related gastritis (two studies, sensitivity 86% (95% CI 76% to 93%, I 2 =0), specificity 93% (95% CI 87% to 97%, I 2 =2.6%)). The pooled analyses demonstrated CLE yields remarkable sensitivity and specificity, in per patient analysis in all three domains.…”